Induction therapy in kidney transplant recipients: A consensus statement of Indian Society of Organ Transplantation

Table 1 Rabbit anti-thymocyte globulin dose used in different kidney recipient populations (n = 254 completed survey)

Type of recipients with specialists using rATG as preferred dose unless otherwise specified	Lowest dose (mg/kg in single dose or given twice if required)	Highest dose (mg/kg in single dose)	Using 1.5 mg/kg dose (in single dose or fraction of cumulative dose)1, %
High immunological risk	0.2	6	10.6 (27/254)
Low immunological risk3	0.25	3	4.7 (12/254)
ABOiKT	0.5	6	7.9 (20/254)
Adults with low immunological risk3	0.25	5	7.5 (19/254)
Adults with high immunological risk	0.25	6	11.4 (29/254)
Elderly	0.5	4	5.1 (13/254)
Adolescents	0.4	5	7.1 (18/254)
Paediatric	0.2	5	9.1 (23/254)
Kidney from living donor with diabetes	0.25	10	11.4 (29/254)
Kidney from SCD	0.2	7-8	8.3 (21/254)
Kidney from ECD	0.2	6	7.9 (20/254)
Kidney from deceased donor with AKI	0.5	5	9.1 (23/254)
Kidney from deceased donor with infection	0.5	32	6.7 (17/254)

¹Includes 1.5 mg as single/3 mg in 2 divided doses/4.5 mg in 3 divided doses.

²Three doses of 3 mg/kg.

³IL-R2A was the preferred therapy.

AKI: Acute kidney injury; ABOiKT: ABO incompatible kidney transplant; ATG: Anti-thymocyte globulin; ECD: Expanded criteria donor; SCD: Standard criteria donor; rATG: Rabbit anti-thymocyte globulin.